1 Hypercholesterolæmi var rapporteret hos op til 5, 3% af de patienter, der blev behandlet med rosiglitazon (oral monoterapi, dobbel - eller tripelterapi).
1 Hypercholesterolaemia was reported in up to 5.3% of patients treated with rosiglitazone (monotherapy, dual or triple oral therapy).